Antiplatelet therapy: current strategies and future trends (Q40329892)

19 September 2017

title

Antiplatelet therapy: current strategies and future trends (English)

1 reference

19 September 2017

4

Paul A Gurbel

1 reference

19 September 2017

Udaya S Tantry

1

1 reference

19 September 2017

Amena Etherington

series ordinal

2

1 reference

19 September 2017

Kevin P Bliden

series ordinal

3

1 reference

19 September 2017

publication date

1 May 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

2

1 reference

19 September 2017

issue

3

1 reference

19 September 2017

page(s)

343-366

1 reference

Platelet activation in myocardial ischemic syndromes

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Resistance to antiplatelet drugs: current status and future research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Platelets in atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Thrombus formation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Signaling events underlying thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

The role of platelet receptors and adhesion molecules in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

The role of platelets in peripheral arterial disease: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Recollections of the development of flow devices for studying mechanisms of hemostasis and thrombosis in flowing whole blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Acetylation of prostaglandin synthase by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Clinical practice. Aspirin for primary prevention of coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Role of antiplatelet drugs in the prevention of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

An Update on Aspirin in the Primary Prevention of Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

The puzzle of aspirin and sex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Comparative effect of aspirin and clopidogrel on arterial function in CHF

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Aspirin use in chronic heart failure: what should we recommend to the practitioner?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Aspirin resistance: definition, mechanisms and clinical read-outs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Regulation of platelet functions by P2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Coronary stenting in stable patients: identification of a low-risk subgroup that may not require adjunctive antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Clopidogrel for percutaneous coronary revascularization: time for more pretreatment, retreatment, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Clopidogrel resistance: implications for coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reop

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

The vascular effects of cilostazol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Circulating serotonin in vertebrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

The evolving role of direct thrombin inhibitors in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

New approaches for antithrombotic antiplatelet therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

CD40 ligand: a novel target in the fight against cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effects of severe hypertension on endothelial and platelet microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Nonfractionated heparin fails to inhibit arterial thrombosis in a human ex vivo thrombosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

A prospective study of aspirin use and primary prevention of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

New antithrombotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.3.343

21 January 2018

Identifiers

DOI

10.2217/14796678.2.3.343

1 reference

19 September 2017

1 reference